GLIOGENE International Case-Control Study of Malignant Glioma
Aims:
The goal of this epidemiological study is to learn about the possible factors that may lead to a higher risk of developing a brain tumor such as genetic and environmental factors, including exposure to radiation and/or chemicals. This study is looking for both individuals who have been diagnosed with a glioma and visitors to the Kellogg Center who have never been diagnosed with cancer
Principal Investigator:
Ryan T. Merrell, MD
IRB Approval Number:
EH08-327
Funding Source:
National Cancer Institute
Contact:
Please call 847.570.2025 with questions regarding the study
Open to Enrollment:
Yes

An International, Randomized, Double-Blind, Controlled Study of Rindopepimut/GM-CSF with Adjuvant Temozolomide in Patients with Newly Diagnosed, Surgically Resected, EGFRvIII-positive Glioblastoma
Aims:
The purpose of this research study is to confirm that the addition of Rindopepimut/GM-CSF to Adjuvant Temozolomide improves the overall survival in participants with newly diagnosed EGFRvIII-positive glioblastoma who have undergone resection
Investigator: Ryan T. Merrell, MD
IRB Approval Number: EH11-311
Funding Source:
Celldex Therapeutics
Contact:
Please call 847.570.2025 with questions regarding the study
Open to Enrollment:
Yes

A Phase II Study of Rindopepimut/GM-CSF in Patients with Relapsed EGFRvIII-Positive Glioblastoma
Aims:
The purpose of this research study is to evaluate whether the addition of the investigational vaccine rindopepimut to bevacizumab can improve the progression free survival of patients with relapsed EGFRvIII positive glioblastoma
Principal Investigator:
Ryan T. Merrell, MD
IRB Approval Number: EH12-095
Funding Source:
Celldex Therapeutics
Contact:
Please call 847.570.2025 with questions regarding the study
Open to Enrollment:
Yes

Randomized, Double-Blind, Placebo-Controlled Trial of Lacosamide for Seizure Prophylaxis in Patients with High-Grade Gliomas
Aims:
The purpose of this study is to find out whether treating with lacosamide reduces the risk of seizures in patients with malignant glioma
Principal Investigator: Ryan T. Merrell, MD
IRB Approval Number:
EH12-175
Funding Source:
Brain Tumor Trials Collaborative (BTTC)/UCB
Contact:
Please call 847.570.2025 with questions regarding the study
Open to Enrollment:
Yes

Natural History of Postoperative Cognitive Function, Quality of Life, and Seizure Control in patients with Supratentorial Low-Risk Grade II Glioma
Aims:
The purpose of this study is to understand the effects of brain tumors and surgery on cognitive function, quality of life and seizures
Principal Investigator:
Ryan T. Merrell, MD
IRB Approval Number:
EH12-467
Funding Source:
Radiation Therapy Oncology Group (RTOG)
Contact:
Please call 847.570.2025 with questions regarding the study
Open to Enrollment:
Yes

A Phase III Randomized, Double-Blind Placebo Controlled Study of Armodafinil (Nuvigil) to Reduce Cancer-Related Fatigue in Patients with Glioblastoma Multiforme
Aims:
The purpose of this study is to determine if taking the drug armodafinil will improve problems with fatigue in patients with glioblastoma and to evaluate the effects of taking armodafinil as compared to placebo on cancer related fatigue and on cognitive function
Principal Investigator:
Ryan T. Merrell, MD
IRB Approval Number:
EH13-248
Funding Source:
Alliance for Clinical Trials in Oncology (Alliance)
Contact:
Please call 847.570.2025 with questions regarding the study
Open to Enrollment:
Yes

N107C, A Phase III Trial of Post-Surgical Stereotactic Radiosurgery (SRS) Compared with Whole Brain Radiotherapy (WBRT) for Resected Metastatic Brain Disease
Aims:
The purpose of this study is to compare overall survival and the effects of stereotactic radiosurgery to whole brain radiation therapy in patients with brain metastases
Principal Investigator:
Ryan T. Merrell, MD
IRB Approval Number:
EH12-368
Funding Source:
North Central Clinical Trial Group (NCCTG) through Alliance for Clinical Trials in Oncology (Alliance)
Contact:
Please call 847.570.2025 with questions regarding the study
Open to Enrollment:
 Yes

RTOG-1122, Phase II Double-Blinded Placebo-Controlled Study of Bevacizumab with or without AMG 386 in Patients with Recurrent Glioblastoma or Gliosarcoma
Aims: The purpose of this research study is to evaluate whether the addition of the investigational drug, AMG 386, to bevacizumab can improve the progression-free survival in patients with relapsed glioblastoma
Principal Investigator: Ryan T. Merrell, MD
IRB Approval Number:
EH13-263
Funding Source:
Radiation Therapy Oncology Group (RTOG)
Contact:
Please call 847.570.2025 with questions regarding the study
Open to Enrollment:
Yes

A Phase II Randomized Trial Comparing the Efficacy of Heat Shock Protein-Peptide Complex-96 (HSPPC-96) (NSC #725085, Alliance IND# 15380) Vaccine Given with Bevacizumab Versus Bevacizumab Alone in the Treatment of Surgically Resectable Recurrent Glioblastoma Multiforme (GBM)
Aims: The purpose of this research study is to evaluate whether the addition HSPPC-96 to bevacizumab can improve the overall survival in patients with resectable recurrent glioblastoma
Principal Investigator: Ryan T. Merrell, MD
IRB Approval Number:
EH13-264
Funding Source:
Alliance for Clinical Trials in Oncology (Alliance)
Contact:
Please call 847.570.2025 with questions regarding the study
Open to Enrollment:
Yes 

Phase I/II Adaptive Randomized Trial of Bevacizumab versus Bevacizumab plus Vorinostat in Adults with Recurrent Glioblastoma
Aims:
The purpose of the Phase II portion of this study is to investigate the effectiveness of vorinostat plus bevacizumab in comparison to bevacizumab treatment alone in patients with recurrent glioblastoma as determined by progression free survival
Principal Investigator:
Nina Martinez, MD
IRB Approval Number:
EH12-452
Funding Source:
Brain Tumor Trials Collaborative (BTTC)
Contact:
Please call 847.570.2025 with questions regarding the study
Open to Enrollment:
Yes

Yellow 560 Microscope for Intraoperative Visualization of Fluorescein Stained High Grade Gliomas
Aims: The purpose of this study is to assess the use of a yellow, fluorescent dye in combination with a specialized microscope during brain surgery for the removal of a specific type of tumor called a high-grade glioma. Objectives include measuring patient outcomes and measuring the extent of tumor removal
Principal Investigator: Julian Bailes, MD
IRB Approval Number:
EH13-331
Funding Source:
NorthShore University HealthSystem
Contact:
Please call Robert Frech at 847.570.4224 with questions regarding the study
Open to Enrollment:
Yes

A Phase 1 Study Evaluating the Safety and Pharmacokinetics of ABT-414 in Combination with Radiation Plus Temozolomide or Temozolomide Alone for Subjects with Glioblastoma Multiforme
Aims
: The purpose of this study is to determine how the drug ABT-414 works in the body and evaluate its safety in patients with newly diagnosed or recurrent glioblastoma
Principal Investigator: Ryan T. Merrell, MD
IRB Approval Number: EH13-332
Funding Source: AbbVie
Contact: Please call 847.570.2025 with questions regarding the study
Open to Enrollment
: Yes

 

× Alternate Text